SCHEMBL14256734

SCHEMBL14256734

CNC(=O)N1CCC(Nc2nc(NCc3ccccc3Sc3ccccc3CO)nc3ccccc23)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EHMT2 Q96KQ7 9/20 0.47
▸ KDM1A O60341 4/20 0.47
▸ DNMT3A Q9Y6K1 1/20 0.45
▸ WHR1 P49842 1/20 0.44
▸ RCOR1 Q9UKL0 3/20 0.41
▸ APP P05067 2/20 0.40
▸ BCHE P06276 1/20 0.40
▸ ACHE P22303 1/20 0.40
▸ MERTK Q12866 1/20 0.40
▸ CXCR4 P61073 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ NTSR1 P30989 1/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14412273 0.90 EHMT2 (0.44) EHMT2KDM1ADNMT3AWHR1RCOR1
SCHEMBL14256736 0.87 DNMT3A (0.53) EHMT2KDM1ADNMT3AWHR1RCOR1
SCHEMBL14266659 0.87 EHMT2 (0.42) EHMT2KDM1ADNMT3AWHR1RCOR1
SCHEMBL14256741 0.85 WHR1 (0.45) EHMT2KDM1ADNMT3AWHR1APP
SCHEMBL14256444 0.84 MERTK (0.53) WHR1APPBCHEACHEMERTK
SCHEMBL14412253 0.84 PDE5A (0.45) EHMT2KDM1ADNMT3AWHR1APP
SCHEMBL14256699 0.83 MERTK (0.52) APPBCHEACHEMERTKCXCR4
SCHEMBL14412248 0.82 APP (0.45) EHMT2KDM1AWHR1APPBCHE
SCHEMBL14412272 0.82 CXCR4 (0.52) WHR1APPBCHEACHEMERTK
SCHEMBL14256700 0.82 APP (0.46) EHMT2KDM1AWHR1APPBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058312-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2008-03-06 — — US disclosed
US-20080058312-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2008-03-06 — — US disclosed
US-20070213319-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2007-09-13 — — US disclosed
US-20070213319-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2007-09-13 — — US disclosed
WO-2007081978-A2 MODULATORS OF HEPATOCYTE GROWTH FACTOR / C-MET ACTIVITY ANGION BIOMEDICA CORPORATION (US) 2007-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213319-A1 Modulators of hepatocyte growth factor/c-Met activity HGF, MET, HDGF EHMT2 1276/4885KDM1A 3012/4885DNMT3A 1041/4885
US-20080058312-A1 Modulators of hepatocyte growth factor/c-Met activity HGF, MET, HDGF EHMT2 1177/4885KDM1A 2734/4885DNMT3A 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback